PBM
Psyence Biomedical Ltd.

2,937
Loading...
Loading...
News
all
press releases
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024
Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.
Stocktwits·8mo ago
News Placeholder
More News
News Placeholder
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships. read more...
Benzinga·1y ago
News Placeholder
Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care
Psyence Biomed initiates a Phase IIb psilocybin trial in Australia to explore its potential as a treatment for Adjustment Disorder. read more...
Benzinga·1y ago
News Placeholder
Psyence Biomedical Shares Clinical Ambitions
Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd. has released an investor presentation highlighting its focus on developing...
TipRanks Financial Blog·1y ago
News Placeholder
Psyence Biomedical Amends Note Agreements
Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd. has entered into an addendum with note holders, facilitating the conversio...
TipRanks Financial Blog·1y ago
News Placeholder
Why Psyence Biomedical (PBM) Stock Is Skyrocketing
Psyence Biomedical shares are trading higher by 73% during Thursday's session. The company announced the export of nature-derived psilocybin to Australia. read more...
Benzinga·1y ago
News Placeholder
Psyence Biomedical Issues Convertible Note
Psyence Biomedical (PBM) has released an update. Psyence Biomedical Ltd. has issued a Senior Secured Convertible Note due July 15, 2027, with a pri...
TipRanks Financial Blog·1y ago
News Placeholder
Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for...
PR Newswire·1y ago
News Placeholder
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
The study, published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog Benefits are thought to include a...
Globe Newswire·1y ago
News Placeholder
Psyence Biomedical gets non-compliance notification from Nasdaq
Psyence Biomedical gets non-compliance notification from Nasdaq...
SeekingAlpha.com: All News·1y ago

Latest PBM News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.